Initiation of Monthly MINODRONATE (cas 127657-42-5) Therapy at an Early Stage After Hip Fracture
-
Add time:08/09/2019 Source:sciencedirect.com
The incidence of second hip fractures occurring within a year of initial fractures is 20%–45%. The high incidence of second hip fractures in this period can be attributed to the rapid bone loss that occurs during this time. Restoring bone mass at an early stage after hip fractures is critical for preventing subsequent fractures. The aim of this study was to investigate the efficacy of monthly MINODRONATE (cas 127657-42-5) therapy (50 mg/4 wk) for preventing bone loss over a 9-mo period following hip fractures. Minodronate was administered monthly to 51 patients (44 females), beginning within 3 mo after hip fracture surgery. The mean (±standard deviation) age of the patients was 82.0 ± 0.9 yr. Demographics, mobility status, bone turnover makers, and bone mineral density (BMD) in the lumbar spine and proximal femur (including femoral neck and total hip BMD) were examined prior to and after 9 mo of treatment. Lumbar BMD was increased by 2.7% ± 4.4% (p < 0.001) compared to the baseline values. However, femoral neck and total hip BMD did not significantly change. Bone formation and resorption markers both decreased by approximately 70% during treatment. Monthly treatment with minodronate did not adversely affect the healing process on the fracture site or the patients' laboratory results. The patients who were independently mobile prior to injury exhibited greater recovery of BMD in the femoral neck during the 9-mo treatment period. Monthly minodronate therapy during the early stages after hip fractures has favorable effects on restoring overall lumbar BMD and contralateral femoral neck BMD in patients with independent mobility prior to fractures.
We also recommend Trading Suppliers and Manufacturers of MINODRONATE (cas 127657-42-5). Pls Click Website Link as below: cas 127657-42-5 suppliers
Prev:Influence on the bone mineral density and bone metabolism marker after the interruption and reinitiation of monthly MINODRONATE (cas 127657-42-5) therapy in postmenopausal women with osteoporosis
Next:Monthly MINODRONATE (cas 127657-42-5) inhibits bone resorption to a greater extent than does monthly risedronate) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- MINODRONATE (cas 127657-42-5), a Newly Developed Nitrogen-Containing Bisphosphonate, Suppresses Melanoma Growth and Improves Survival in Nude Mice by Blocking Vascular Endothelial Growth Factor Signaling08/17/2019
- MINODRONATE (cas 127657-42-5), a nitrogen-containing bisphosphonate, is a promising remedy for treating patients with diabetic retinopathy08/16/2019
- A double-blinded head-to-head trial of MINODRONATE (cas 127657-42-5) and alendronate in women with postmenopausal osteoporosis08/15/2019
- Comparison of effectiveness and safety of ibandronate and MINODRONATE (cas 127657-42-5) combined with eldecalcitol in primary osteoporosis of women: A 1-year follow-up study08/14/2019
- Effects of MINODRONATE (cas 127657-42-5) on cortical bone response to mechanical loading in rats08/13/2019
- Combined treatment with MINODRONATE (cas 127657-42-5) and vitamin C increases bone mineral density and strength in vitamin C-deficient rats08/12/2019
- Effect of MINODRONATE (cas 127657-42-5) on the speed of sound of the calcaneus in postmenopausal women with an increased risk of fractures: A clinical practice-based observational study08/11/2019
- Monthly MINODRONATE (cas 127657-42-5) inhibits bone resorption to a greater extent than does monthly risedronate08/10/2019
- Influence on the bone mineral density and bone metabolism marker after the interruption and reinitiation of monthly MINODRONATE (cas 127657-42-5) therapy in postmenopausal women with osteoporosis08/08/2019
